Table 1. Declined human kidney characteristics and experimental conditions.
Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | Case 8 | |
---|---|---|---|---|---|---|---|---|
Donor age (years) | 57 | 25 | 44 | 68 | 45 | 64 | 65 | 57 |
Donor type (DBD/DCD) | DCD | DBD | DCD | DBD | DBD | DCD | DCD | DCD |
Left/right kidney | Left | Right | Right | Right | Left | Left | Left | Left |
Reason for decline | Poor in situ perfusion | Malignancy | Suspected malignancy | Suspected malignancy | Poor in situ perfusion + prolonged agonal phase | Suspected malignancy | Histological changes consistent with diabetes | Damage to ureter and artery |
Warm ischemic time (min) | 13 | — | 13 | — | — | 12 | 14 | 11 |
Cold ischemic time (hour:min) | 13:13 | 17:17 | 34:37 | 16:03 | 22:38 | 27:05 | 18:20 | 25:58 |
NMP duration (hour:min) | 4:30 | 6:50 | 5:45 | 5:00 | 5:00 | 8:30 | 8:30 | 8:30 |
Mean RBF (ml/min per 100 g) | 88.0 ± 19.6 | 123.7 ± 35.2 | 91.6 ± 23.9 | 67.9 ± 31.7 | 83.5 ± 35.5 | 75.0 ± 22.1 | 77.3 ± 25.4 | 80.7 ± 37.7 |
Total urine output (ml) | 177 | 730 | 107 | 1045 | 373 | 598 | 451 | 257 |
Macroscopic appearance | Moderate | Moderate | Moderate | Moderate | Moderate | Excellent | Excellent | Moderate |
NP type | CD31-NP | Control-NP | CD31-NP + Control-NP | CD31-NP + Control-NP | CD31-NP + Control-NP | CD31-NP + Control-NP | CD31-NP + Control-NP | CD31-NP + Control-NP |
NP circulating concentration | 4 μg/ml | 4 μg/ml | 10 μg/ml | 50 μg/ml | 100 μg/ml | 50 μg/ml | 50 μg/ml | 50 μg/ml |
NP administration time (from start of perfusion) | 30 min | 50 min | 45 min | 75 min | 60 min | 30 min | 30 min | 30 min |